[go: up one dir, main page]

DK3888658T3 - Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil - Google Patents

Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil Download PDF

Info

Publication number
DK3888658T3
DK3888658T3 DK21153153.8T DK21153153T DK3888658T3 DK 3888658 T3 DK3888658 T3 DK 3888658T3 DK 21153153 T DK21153153 T DK 21153153T DK 3888658 T3 DK3888658 T3 DK 3888658T3
Authority
DK
Denmark
Prior art keywords
eif4
methods related
inhibiting compounds
inhibiting
compounds
Prior art date
Application number
DK21153153.8T
Other languages
English (en)
Inventor
Justin T Ernst
Siegfried H Reich
Paul A Sprengeler
Chinh Tran
Garrick Kenneth PACKARD
Alan Xin Xiang
Christian Nilewski
Theodore Michels
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Application granted granted Critical
Publication of DK3888658T3 publication Critical patent/DK3888658T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK21153153.8T 2015-11-25 2016-11-22 Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil DK3888658T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259828P 2015-11-25 2015-11-25
US201662334149P 2016-05-10 2016-05-10
EP16869174.9A EP3380101B1 (en) 2015-11-25 2016-11-22 Eif4-a-inhibiting compounds and methods related thereto

Publications (1)

Publication Number Publication Date
DK3888658T3 true DK3888658T3 (da) 2024-03-18

Family

ID=58720397

Family Applications (2)

Application Number Title Priority Date Filing Date
DK21153153.8T DK3888658T3 (da) 2015-11-25 2016-11-22 Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK16869174.9T DK3380101T3 (da) 2015-11-25 2016-11-22 Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK16869174.9T DK3380101T3 (da) 2015-11-25 2016-11-22 Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil

Country Status (21)

Country Link
US (5) US9957277B2 (da)
EP (2) EP3888658B1 (da)
JP (1) JP7105691B2 (da)
KR (1) KR20180096644A (da)
CN (1) CN108601788B (da)
AU (1) AU2016359617B2 (da)
CL (1) CL2018001411A1 (da)
CO (1) CO2018006475A2 (da)
DK (2) DK3888658T3 (da)
EA (1) EA037370B1 (da)
ES (2) ES2974439T3 (da)
FI (1) FI3888658T3 (da)
IL (1) IL259433B (da)
MX (1) MX383051B (da)
MY (1) MY196749A (da)
PE (1) PE20181303A1 (da)
PH (1) PH12018501073A1 (da)
SG (2) SG10202004793YA (da)
TW (1) TWI731899B (da)
WO (1) WO2017091585A1 (da)
ZA (1) ZA201804070B (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
EP3099677A4 (en) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
WO2016081203A2 (en) 2014-11-17 2016-05-26 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
KR20180049058A (ko) 2015-09-11 2018-05-10 다나-파버 캔서 인스티튜트 인크. 시아노 티에노트리아졸로디아제핀 및 그의 용도
MX2018003030A (es) 2015-09-11 2018-04-11 Dana Farber Cancer Inst Inc Acetamida tienotriazolodiazepinas y usos de las mismas.
CA3004798C (en) 2015-11-25 2023-10-31 Gilead Apollo, Llc Ester acc inhibitors and uses thereof
KR20180096644A (ko) 2015-11-25 2018-08-29 이펙터 테라퓨틱스, 인크. Eif4a-억제 화합물 및 이에 관련된 방법
JP7385356B2 (ja) 2015-11-25 2023-11-22 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド 二価ブロモドメインインヒビターおよびそれらの使用
CA3004796C (en) 2015-11-25 2023-11-14 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
PL3380479T3 (pl) 2015-11-25 2023-05-08 Gilead Apollo, Llc Triazolowe inhibitory acc i ich zastosowania
EA201890910A1 (ru) 2015-11-25 2018-11-30 Джилид Аполло, Ллс ФУНГИЦИДНЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 2,4-ДИОКСО-1,4-ДИГИДРОТИЕНО[2,3-d]ПИРИМИДИНА
KR20200013665A (ko) * 2017-05-04 2020-02-07 아이크노스 사이언스 에스. 아. Nadph 옥시다아제 억제제로서 치환된 바이사이클릭 헤테로사이클릭 화합물
EP3630108A1 (en) 2017-05-24 2020-04-08 Effector Therapeutics Inc. Compositions and methods for an improved antitumor immune response
WO2019161345A1 (en) * 2018-02-19 2019-08-22 Memorial Sloan-Kettering Cancer Center Agents and methods for treating dysproliferative diseases
SI3773544T1 (sl) 2018-04-10 2026-01-30 Cellectar Biosciences, Inc. Fosfolipid-flavaglin konjugati ter postopki njihove uporabe za ciljno zdravljenje raka
CN109503418B (zh) * 2018-12-11 2021-06-08 河北合佳医药科技集团股份有限公司 一种甲基肼的制备工艺
US20220151976A1 (en) * 2019-02-18 2022-05-19 The University Of Toledo Targeting lasp1, eif4a1, eif4b and cxc4 with modulators and combinations thereof for cancer therapy
CN109971762B (zh) * 2019-04-24 2022-12-20 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 日本血吸虫eIF4A基因的siRNA及其应用
US12496346B2 (en) 2019-10-10 2025-12-16 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
WO2021195128A1 (en) * 2020-03-24 2021-09-30 Effector Therapeutics, Inc. Eif4a inhibitor combinations
TW202221003A (zh) * 2020-10-28 2022-06-01 大陸商上海翰森生物醫藥科技有限公司 多環類生物調節劑、其製備方法和應用
CN112574078B (zh) * 2020-12-14 2022-09-13 湖南工程学院 2-砜基-2，3-二氢-1-茚酮及其衍生物及合成方法
EP4395775A1 (en) 2021-09-01 2024-07-10 KHR Biotec GmbH Cyclopenta[4,5]furo[3,2-c]pyridine derivatives as ras inhibitors for use in the treatment of hyperproliferative diseases or genetic disorders
AU2022340664A1 (en) 2021-09-01 2024-03-14 Sjp Biotec Gmbh Novel ras inhibitors
CN115448860B (zh) * 2022-09-16 2024-04-02 上海海客宜家生物科技有限公司 一种邻甲硫基苯甲腈的合成方法
CN120731200A (zh) 2023-02-23 2025-09-30 Sjp生物技术有限公司 作为ras抑制剂的3-ah环戊二烯并[b]苯并呋喃-3a-基化合物
WO2024175662A1 (en) 2023-02-23 2024-08-29 KHR Biotec GmbH Flavagline derivatives as ras inhibitors
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025039073A1 (en) * 2023-08-18 2025-02-27 The Royal Institution For The Advancement Of Learning/Mcgill University Rna helicase inhibitor
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
TW202519522A (zh) * 2023-11-03 2025-05-16 大陸商映恩生物製藥（蘇州）有限公司 蛋白轉譯抑制劑
CN117700387A (zh) * 2023-11-30 2024-03-15 深圳湾实验室 类洛克米兰醇化合物、中间体及制备方法和应用
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19934952A1 (de) 1998-07-30 2000-02-03 Novartis Ag Cyclopentabenzofuran-Derivate
DE10356218A1 (de) 2003-12-03 2005-06-30 Bayer Cropscience Ag Verfahren zum Identifizieren von fungizid wirksamen Verbindungen basierend auf Pyruvatkinasen aus Pilzen
CA2560740A1 (en) 2004-03-23 2006-10-06 Trustees Of Boston University Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species
DE102004024504A1 (de) 2004-05-18 2006-02-16 Bayer Healthcare Ag Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
WO2006007634A1 (en) 2004-07-16 2006-01-26 Cerylid Biosciences Ltd Processes and intermediates
EP1693059A1 (en) 2005-02-22 2006-08-23 Deutsches Krebsforschungszentrum Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases
CN100418532C (zh) 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
WO2007139749A2 (en) 2006-05-22 2007-12-06 Trustees Of Boston University Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids
EP2189453A1 (en) 2008-11-25 2010-05-26 Université Louis Pasteur Rocaglaol derivatives as cardioprotectant agents
WO2011140334A2 (en) 2010-05-06 2011-11-10 Trustees Of Boston University Compounds, methods of making or identifying compounds, and uses thereof
EP2457907A1 (en) 2010-11-16 2012-05-30 Université de Strasbourg Flavagline derivatives as neuroprotective agents
CN103328452A (zh) * 2010-12-13 2013-09-25 威尔金制药有限公司 金属酶抑制剂化合物
US20140255432A1 (en) 2011-07-27 2014-09-11 Ohio State Innovation Foundation Silvestrol, silvestrol analogs and uses thereof
US20150087598A1 (en) * 2012-05-11 2015-03-26 Dana-Farber Cancer Institute, Inc. Treating muc1-expressing cancers with helicase inhibitors
US20160158189A1 (en) 2013-07-17 2016-06-09 Deutsches Krebsforschungszentrum Sensitization of cancer cells to apoptosis induction by flavaglines and 5-hydroxy-flavones
WO2015075165A1 (en) 2013-11-22 2015-05-28 Deutsches Krebsforschungszentrum Translation inhibitors in high-dose chemo- and/or high-dose radiotherapy
FR3023290B1 (fr) 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
KR20180096644A (ko) 2015-11-25 2018-08-29 이펙터 테라퓨틱스, 인크. Eif4a-억제 화합물 및 이에 관련된 방법

Also Published As

Publication number Publication date
KR20180096644A (ko) 2018-08-29
NZ743453A (en) 2024-07-26
US20230071483A1 (en) 2023-03-09
US10577378B2 (en) 2020-03-03
PH12018501073A1 (en) 2019-01-21
JP7105691B2 (ja) 2022-07-25
US20230295179A1 (en) 2023-09-21
EP3380101B1 (en) 2021-01-27
SG11201804132UA (en) 2018-06-28
EP3888658A1 (en) 2021-10-06
CA3006041A1 (en) 2017-06-01
PE20181303A1 (es) 2018-08-09
IL259433B (en) 2021-05-31
ZA201804070B (en) 2021-10-27
SG10202004793YA (en) 2020-06-29
CN108601788B (zh) 2021-10-22
CO2018006475A2 (es) 2018-07-10
AU2016359617A1 (en) 2018-07-05
AU2016359617B2 (en) 2022-04-14
US20180298017A1 (en) 2018-10-18
EA037370B1 (ru) 2021-03-19
EP3380101A4 (en) 2019-05-22
BR112018010235A2 (pt) 2019-03-19
DK3380101T3 (da) 2021-04-26
ES2974439T3 (es) 2024-06-27
EA201891229A1 (ru) 2018-12-28
EP3380101A1 (en) 2018-10-03
MX383051B (es) 2025-03-13
US20200339590A1 (en) 2020-10-29
ES2870037T3 (es) 2021-10-26
MY196749A (en) 2023-05-03
TWI731899B (zh) 2021-07-01
MX2018006443A (es) 2019-08-01
JP2019500331A (ja) 2019-01-10
IL259433A (en) 2018-07-31
EP3888658B1 (en) 2023-12-27
TW201731832A (zh) 2017-09-16
CN108601788A (zh) 2018-09-28
WO2017091585A1 (en) 2017-06-01
US9957277B2 (en) 2018-05-01
FI3888658T3 (fi) 2024-03-22
US20170145026A1 (en) 2017-05-25
US11440917B2 (en) 2022-09-13
CL2018001411A1 (es) 2018-11-30

Similar Documents

Publication Publication Date Title
DK3888658T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
IL280863A (en) Autotaxin inhibitors and uses thereof
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3310371T3 (da) Glucagon og GLP-1-Co-agonistforbindelser
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3092256T3 (da) Forbindelser og sammensætninger til immunterapi
DK3442972T3 (da) Bromdomænehæmmere
DK3212189T3 (da) Substituerede chromaner og fremgangsmåde til anvendelse deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3212218T3 (da) GIP-agonistforbindelser og fremgangsmåder
DK3237418T3 (da) Triazolopyrimidinforbindelser og anvendelser deraf
DK3316909T3 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
DK3210977T3 (da) Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3193611T3 (da) Mk2-inhibitorer og anvendelser deraf
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3353168T3 (da) Forbindelser og fremgangsmåder til at inhibere jak
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3395801T3 (da) Arylazolforbindelse og skadedyrsbekæmpelsesmiddel
DK3271347T3 (da) Antifungale forbindelser og fremstillingsfremgangsmåder
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf